Probi AB and Clasado Biosciences announce new partnership


The intention of the partnership is to leverage their respective portfolios of probiotics and prebiotics to develop synbiotics

Photo ©

Photo ©

Probi AB (Lund, Sweden) and Clasado Biosciences (Reading, UK) have announced a partnership to leverage their respective portfolios of probiotics and prebiotics to develop synbiotics.

"It’s an exciting period of growth for the biotics category, and we are delighted to be partnering with Probi to collaborate around our respective areas of expertise,” said Per Rehné, CEO of Clasado, in a press release from the company. “Through this collaboration, we aim to pool our knowledge and scientific research capabilities to build a firmer and credible foundation for synbiotic product development, particularly in priority health areas. In turn, we believe this scientific-led partnership will benefit health and nutrition customers globally, as well as end users.”

According to Rehné, Clasado’s Bimuno GOS is the most studied galactooligosaccharide ingredient on the market with more than 110 scientific publications, including 20 clinical trials. Combined with Probi’s probiotic library that is supported by preclinical and clinical trials, the partnership makes for a great match, he explains in the release.

"In the accelerating health and wellbeing market, consumers are responding to new scientifically backed products, and our shared commitment to empirical trial-based evidence makes this a partnership with great potential,” said Anita Johansen, CEO of Probi in the release. “Propelled by consumer demand for better gut microbiome health, the market for synbiotics is expanding at speed, but advanced study and a dedicated research program could make this growth exponential. Through this partnership, we’ll be exploring how products in our probiotic library can function alongside Bimuno GOS in formulations, and we hope to set the bar for synbiotic collaboration.”

Related Videos
woman working on laptop computer by window
Related Content
© 2024 MJH Life Sciences

All rights reserved.